Status:
COMPLETED
Feasibility of Expressive Writing for Body Image Distress and Anxiety Among Adolescent and Young Adult Cancer Survivors
Lead Sponsor:
University of Michigan Rogel Cancer Center
Collaborating Sponsors:
American Society of Clinical Oncology
Conditions:
Adolescent Cancer
Young Adult Cancer
Eligibility:
All Genders
15-39 years
Phase:
NA
Brief Summary
Each year, about 89,500 adolescents and young adults (AYAs; 15-39 years old) are diagnosed with cancer and up to 60% experience body image (BI) distress. BI is largely developed in adolescence and you...
Detailed Description
Protocol was updated to make the previous secondary outcome measures now exploratory
Eligibility Criteria
Inclusion
- Age 15-39 years
- History of one or more cancer diagnoses with all treatment (surgery, chemotherapy, radiation) completed ≥ 3 months before enrollment)
- BIS ≥10 at time of screening
- Ability to provide consent or assent and parental consent if applicable.
Exclusion
- Plan to receive surgery, radiation, chemotherapy (including biologic agents, immunotherapy, and other targeted agents) for cancer treatment during the study period (from baseline assessment through post-four-week assessments and interview). Participants may continue with surveillance (such as imaging or biopsies) during the study period.
- Initiation of new treatments for body image distress or anxiety (e.g., pharmacologic, psychotherapy) ≤8 weeks prior to study enrollment. Although, participants may continue psychosocial or pharmacological treatments for anxiety or body image distress if the treatment were initiated at least eight weeks prior to study enrollment, the dose has not changed, and they report clinically relevant body image distress.
- History of limb-altering surgery or amputation (surgical exclusions are based on the premise that significant appearance-altering surgeries may impact body image distress differently than other cancer therapies)
- Currently receiving end-of-life care
Key Trial Info
Start Date :
September 14 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06046014
Start Date
September 14 2024
End Date
June 1 2025
Last Update
September 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States, 48109